Back to home

Complete life cycle of an Easyhaler assessed

Insights | 25/08/2020
  • Orion has conducted a comprehensive life cycle assessment (LCA) of four products in the Easyhaler range to further understand their environmental impact.
  • The average carbon footprint from a single Easyhaler was 0.588 kg CO₂ equivalents (CO₂e) from which the major part (60%) was associated with the manufacturing process.
  • As a result of this thorough assessment of the carbon emissions associated with an Easyhaler, Orion is now qualified to use Carbon Footprint Standard.

The fundamental discussion about climate change also intersects with the healthcare sector, including the treatment of asthma and COPD. Easyhalers are plastic inhalers used to distribute dry-powder active pharmaceutical ingredients (APIs) to their site of action. In order to examine the carbon emissions and environmental impact associated with their product, Orion has conducted a comprehensive LCA for Easyhaler. This assessment covers carbon footprint produced throughout the product life cycle, from raw material sourcing and manufacturing to distribution and final end-of-life disposal.

The carbon LCA, was conducted for different Easyhaler products:

The average carbon footprint of a single Easyhaler in this assessment was 0.588 kg CO₂e. Of the four Easyhaler products addressed, the combination product Bufomix (budesonide-formoterol) Easyhaler produced the smallest carbon load of 0.514 kg CO₂e. In all cases, the majority of carbon emissions (approximately 60%) was associated with inhaler manufacturing whereas distribution accounted for less than 2% of the emissions (Figure 1). Manufacturing stage was also the major source of variation between inhalers resulting mainly from different APIs and quantities of the lactose carrier. The breakdown of carbon emissions at different life cycle stages of Bufomix Easyhaler is provided in Table 1.

Figure 1. Breakdown of Carbon Emissions from a single Easyhaler

The values are averaged for the products tested.


Table 1. Breakdown of carbon emissions from Bufomix Easyhalers

Of the four Easyhaler products assessed, the combination product Bufomix (budesonide-formoterol) Easyhaler produced the smallest carbon footprint.


Addressing the major environmental challenges of modern times calls for a sustainability perspective in all decision making. While the patient’s needs are, and always should be, the primary criteria in selecting the inhaler, the sustainability of the product is a significant value to consider and discuss when weighing equally efficient options.

Orion in conjunction with Carbon Footprint Ltd, has assessed the average cradle-to-grave carbon emissions associated with Easyhaler. As a result, Orion has qualified to use the Carbon Footprint Standard.

The availability of Easyhaler products varies between countries. Bufomix (budesonide-formoterol) Easyhaler is the only preparation available in the Republic of Ireland.


Prescribing information available here


Easyhaler Carbon Life Cycle Assessment Report, Executive Summary 2020, Carbon Footprint Ltd. Available at:


Date of preparation: July 2020 / EASYH-886


Adverse effects should be reported. You can report side effects directly via the Health Products Regulatory Authority (HPRA) website: or by email on Adverse effects should also be reported to Orion Pharma via
Orion Pharma (Ireland) Ltd., C/o Allphar Serivces, 4045 Kingswood Rd, Citywest Business Pk, Dublin 24. Tel +353 1 4687500 Date of Preparation February 2020 / EASYH-638
Policies Contact us Orion Corporation 2021